Exagen Inc. (XGN)

Market Cap	148.21M
Revenue (ttm)	56.72M
Net Income (ttm)	-15.51M
Shares Out	21.86M
EPS (ttm)	-0.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	134,570
Open	7.08
Previous Close	7.07
Day's Range	6.79 - 7.13
52-Week Range	1.78 - 7.95
Beta	1.58
Analysts	Strong Buy
Price Target	7.50 (+10.46%)
Earnings Date	Jul 29, 2025

About XGN

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and ot...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Sep 19, 2019
• Employees: 215
• Stock Exchange: NASDAQ
• Ticker Symbol: XGN
• Website: https://www.exagen.com

Financial Performance

In 2024, Exagen's revenue was $55.64 million, an increase of 5.89% compared to the previous year's $52.55 million. Losses were -$15.12 million, -36.19% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for XGN stock is "Strong Buy." The 12-month stock price target is $7.5, which is an increase of 10.46% from the latest price.

Price Target

$7.5

(10.46% upside)

Analyst Consensus: Strong Buy